Equities research analysts forecast that Flexion Therapeutics Inc (NASDAQ:FLXN) will report earnings of ($1.24) per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Flexion Therapeutics’ earnings. The lowest EPS estimate is ($1.35) and the highest is ($1.14). Flexion Therapeutics reported earnings of ($1.07) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 15.9%. The company is expected to report its next quarterly earnings report on Monday, November 5th.

On average, analysts expect that Flexion Therapeutics will report full-year earnings of ($4.75) per share for the current year, with EPS estimates ranging from ($4.92) to ($4.63). For the next year, analysts expect that the business will post earnings of ($2.74) per share, with EPS estimates ranging from ($3.31) to ($1.53). Zacks’ earnings per share averages are an average based on a survey of research analysts that cover Flexion Therapeutics.

Flexion Therapeutics (NASDAQ:FLXN) last posted its earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported ($1.16) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.22) by $0.06. The firm had revenue of $3.80 million during the quarter, compared to analyst estimates of $3.96 million.

Several analysts have weighed in on FLXN shares. BidaskClub lowered Flexion Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, September 12th. Zacks Investment Research lowered Flexion Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, August 13th. ValuEngine raised Flexion Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 2nd. Finally, Benchmark started coverage on Flexion Therapeutics in a report on Thursday, June 28th. They issued a “buy” rating and a $39.00 target price on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $91.50.

In related news, CFO David Arkowitz acquired 4,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 9th. The shares were acquired at an average price of $23.42 per share, with a total value of $93,680.00. Following the completion of the purchase, the chief financial officer now directly owns 44,250 shares in the company, valued at $1,036,335. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, insider Neil Bodick sold 50,000 shares of the stock in a transaction on Tuesday, July 3rd. The shares were sold at an average price of $25.07, for a total value of $1,253,500.00. The disclosure for this sale can be found here. 14.59% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. State Board of Administration of Florida Retirement System boosted its stake in shares of Flexion Therapeutics by 22.9% during the second quarter. State Board of Administration of Florida Retirement System now owns 15,896 shares of the specialty pharmaceutical company’s stock valued at $411,000 after acquiring an additional 2,960 shares during the last quarter. Redmile Group LLC boosted its stake in shares of Flexion Therapeutics by 33.5% during the second quarter. Redmile Group LLC now owns 13,260 shares of the specialty pharmaceutical company’s stock valued at $343,000 after acquiring an additional 3,330 shares during the last quarter. Swiss National Bank boosted its stake in shares of Flexion Therapeutics by 7.1% during the first quarter. Swiss National Bank now owns 51,311 shares of the specialty pharmaceutical company’s stock valued at $1,150,000 after acquiring an additional 3,400 shares during the last quarter. Alps Advisors Inc. boosted its stake in shares of Flexion Therapeutics by 8.5% during the second quarter. Alps Advisors Inc. now owns 54,622 shares of the specialty pharmaceutical company’s stock valued at $1,412,000 after acquiring an additional 4,272 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its stake in shares of Flexion Therapeutics by 3.0% during the second quarter. Schwab Charles Investment Management Inc. now owns 179,658 shares of the specialty pharmaceutical company’s stock valued at $4,645,000 after acquiring an additional 5,257 shares during the last quarter. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Flexion Therapeutics stock traded up $0.07 during trading hours on Tuesday, hitting $19.80. The stock had a trading volume of 469,800 shares, compared to its average volume of 593,652. The company has a debt-to-equity ratio of 0.80, a quick ratio of 12.78 and a current ratio of 12.90. The firm has a market capitalization of $783.54 million, a price-to-earnings ratio of -4.76 and a beta of 0.72. Flexion Therapeutics has a 1-year low of $19.06 and a 1-year high of $32.25.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.

Recommended Story: Short Selling Stocks and Day Traders

Get a free copy of the Zacks research report on Flexion Therapeutics (FLXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.